---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-000811"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2025-01-03T23:59:59+00:00"
generated_at: "2026-05-28T12:31:48.426668+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents reports preliminary Q4 product revenue $9.0M-$9.2M, 22-25% YoY growth; full-year ~$35.5M, 14% growth

## Summary
- Q4 2024 product revenue est $9.0M-$9.2M, 22-25% YoY growth vs $7.35M in Q4 2023.
- Full-year 2024 product revenue est $35.4M-$35.6M, ~14% growth vs $31.1M in FY 2023.
- Q4 gross margin est ~70%, up from 61% in Q3 2024, driven by resolution of manufacturing issues.
- Rights offering commenced Dec 23, 2024; subscription period ends Jan 10, 2025.
- FDA and Health Canada reviews for DrugSorb-ATR marketing application underway; decisions expected in 2025.

## SEC filing metadata
- accession: 0001104659-25-000811
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2025-01-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465925000811/0001104659-25-000811-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465925000811/tm251882d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-000811
- JSON: https://secwatch.observer/filing/0001104659-25-000811.json
- Plain text: https://secwatch.observer/filing/0001104659-25-000811.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.